Monthly Archives: March 2012

No proof of drug industry sway on WHO in pandemic: report (Reuters) – Independent experts who examined the World Health Organisation’s handling of the H1N1 pandemic said on Thursday they had found no evidence of drug industry influence on the … Continue reading →

Drug heist could yield $43m CAREFUL planning by three thieves carrying sledgehammers has enabled them to make off with pharmaceutical drugs that carry a potential street value of $43 million. The drugs, 50 kilograms of pseudoephedrine and 67 kilograms of … Continue reading →

Ironwood Pharmaceuticals Provides Fourth Quarter 2010 Investor Update Linaclotide In November, Ironwood and its U.S. partner, Forest Laboratories, Inc., completed the clinical efficacy portion of the linaclotide development program to support upcoming regulatory submissions in both the U.S. and the … Continue reading →

Fixed ARV pricing may hamper Aspen’s growth Aspen Pharmacare, Africa’s largest pharmaceutical manufacturer has announced a 33% increase in revenue for the six months to December 32 last year but warns that performance may decline due to single exit prices … Continue reading →

Increased excise duty, MAT on SEZs to hurt pharma industry Leading drug makers on Tuesday said that higher excise duty proposed in the Budget 2011-12 would make medicines costlier and hurt the common man. Further, pharmaceutical industry players also feared … Continue reading →